# The PK Characteristics of the Co-administration of Metformin SR and Rosuvastatin and JLP-1310 in Healthy Male Volunteers.

> **NCT03690778** · PHASE1 · COMPLETED · sponsor: **Jeil Pharmaceutical Co., Ltd.** · enrollment: 42 (actual)

## Conditions studied

- Diabetes
- Hyperlipidemias

## Interventions

- **DRUG:** "Metformin" and "Rosuvastatin" seperately
- **DRUG:** JLP-1310

## Key facts

- **NCT ID:** NCT03690778
- **Lead sponsor:** Jeil Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-04
- **Primary completion:** 2019-02-01
- **Final completion:** 2019-02-01
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2019-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03690778

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03690778, "The PK Characteristics of the Co-administration of Metformin SR and Rosuvastatin and JLP-1310 in Healthy Male Volunteers.". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT03690778. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*